Post-effective Amendment to Registration Statement (pos Am)
March 13 2020 - 12:11PM
Edgar (US Regulatory)
As filed with
the Securities and Exchange Commission on March 13,
2020
Registration Nos.
333-231951 and 333-234673
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT
NO. 6
TO
FORM S-1
REGISTRATION
STATEMENT
Under
THE SECURITIES ACT
OF 1933
EMERALD BIOSCIENCE, INC.
|
(Exact Name of
Registrant as Specified in its Charter)
|
Nevada
|
|
2834
|
|
45-0692882
|
(State or other
jurisdiction of
incorporation or
organization)
|
|
(Primary Standard
Industrial
Classification Code
Number)
|
|
(I.R.S. Employer
Identification
Number)
|
130 North Marina
Drive
Long Beach, CA
90803
(949)
336-3443
(Address, including zip
code, and telephone number, including area code, of registrant’s
principal executive offices)
Dr. Brian
Murphy
Chief Executive
Officer
Emerald
Bioscience, Inc.
130 North Marina
Drive
Long Beach, CA
90803
(949)
336-3443
(Name, address,
including zip code, and telephone number, including area code, of
agent for service)
___________________
Copies of all
correspondence to:
Douglas
Cesario
|
Mark C. Lee,
Esq.
|
Chief Financial
Officer
|
Greenberg Traurig,
LLP
|
Emerald Bioscience,
Inc.
|
1201 K Street, Suite
1100
|
130 North Marina
Drive
|
Sacramento, CA 95814
|
Long Beach, CA 90803
|
Tel: (916) 868-063
|
Tel: (949) 336-3443
|
|
Fax: (949) 266-0346
|
|
Approximate
date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this
registration statement.
If any of the
securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. ☐
If this Form is filed
to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
☐
If this Form is a
post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration
statement for the same offering. ☐
If this Form is a
post-effective amendment filed pursuant to Rule 462(d) under the
Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration
statement for the same offering. ☐
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, a smaller reporting company or an
emerging growth company. See the definitions of “large accelerated
filer,” “accelerated filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller
reporting company
|
☒
|
Emerging
growth company
|
☐
|
|
|
If an emerging growth
company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or
revised financial accounting standards provided to Section
7(a)(2)(B) of the Securities Act. ☐
DEREGISTRATION
OF SECURITIES
The
registrant is filing this Post-Effective Amendment No. 6 to Form
S-1 to amend its registration statements (Registration Nos.
333-231951 and 333-234673), initially filed with the Securities and
Exchange Commission (the “SEC”) on June 4, 2019 and November 13,
2019, respectively (the “Registration Statements”), to deregister
all securities registered pursuant to the Registration Statements
and not otherwise sold pursuant the securities purchase agreement
described in the current report on the Form 8-K filed with the SEC
on November 21, 2019 as of the date this post-effective amendment
is filed. In accordance with an undertaking made by the Company in
the Registration Statements to remove from registration, by means
of a post-effective amendment, any securities which remain unsold
at the termination of the offering, the Company hereby removes from
registration all securities registered under the Registration
Statements that remain unsold as of the date hereof.
SIGNATURES
Pursuant to the requirements of the
Securities Act, the registrant has duly caused this Registration
Statement to be signed on its behalf by the undersigned thereunto
duly authorized in the City of Long Beach, State of California on
March 13, 2020.
|
Emerald Bioscience, Inc. |
|
|
a Nevada corporation
|
|
|
|
|
|
March 13, 2020 |
By: |
/s/ Brian S.
Murphy |
|
|
Its:
|
Dr. Brian S. Murphy |
|
|
|
Chief Executive Officer, Director |
|
|
|
(Principal Executive Officer) |
|
Pursuant to the requirements of the
Securities Act, this Registration Statement has been signed by the
following persons in the capacities and on the dates indicated.
By:
|
/s/ Brian S. Murphy
|
|
March 13, 2020
|
|
|
Brian S. Murphy
|
|
|
|
Its:
|
Chief Executive Officer, Director
|
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Douglas Cesario
|
|
March 13, 2020
|
|
|
Douglas Cesario
|
|
|
|
Its:
|
Chief Financial Officer
|
|
|
|
|
(Principal Financial and Accounting
Officer)
|
|
|
|
|
|
|
|
|
By:
|
*
|
|
March 13, 2020
|
|
|
Punit Dhillon
|
|
|
|
Its:
|
Chairman
|
|
|
|
|
|
|
|
|
By:
|
*
|
|
March 13, 2020
|
|
|
Jim Heppell
|
|
|
|
Its:
|
Director
|
|
|
|
|
|
|
|
|
*By:
|
/s/ Brian S. Murphy
|
|
|
|
|
Brian S. Murphy
|
|
|
|
|
Attorney-in-Fact
|
|
|
|